Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 128

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 128
---
 Income. Finance
income in during the current and prior period included gains in respect of an equity settled derivative financial liability of £0.75
million and £0.39, million respectively. The gains arose as a result of the fall in our share price. In addition, we earned interest
on cash deposits.

Finance Expense. Finance
expense in the period related to lease liabilities and discounted interest on deferred consideration.

Year Ended December 31, 2023 Compared to Year Ended December 31, 2022

The following table summarizes our consolidated
results of operations for the years ended December 31, 2023 and 2022:

|                                                            |     | Year Ended December 31, |   2023 |   |     |     |   2022 |   |
|:-----------------------------------------------------------|:----|:------------------------|-------:|:--|:----|:----|-------:|:--|
|                                                            |     | -£ in thousands         |        |   |     |     |        |   |
| Revenue                                                    |     |                         |    381 |   |     |     |    699 |   |
| Total revenue                                              |     |                         |    381 |   |     |     |    699 |   |
| Other income                                               |     |                         |     14 |   |     |     |     22 |   |
| Research and development costs                             |     |                         | (4,067 | ) |     |     | (5,111 | ) |
| Administrative costs                                       |     |                         | (4,342 | ) |     |     | (4,542 | ) |
| Loss from operations                                       |     |                         | (8,014 | ) |     |     | (8,932 | ) |
| Finance income                                             |     |                         |    570 |   |     |     |    497 |   |
| Finance expense                                            |     |                         |    (41 | ) |     |     |    (53 | ) |
| Loss before taxation                                       |     |                         | (7,485 | ) |     |     | (8,488 | ) |
| Taxation                                                   |     |                         |    406 |   |     |     |    832 |   |
| Loss from continuing operations                            |     |                         | (7,079 | ) |     |     | (7,656 | ) |
| Loss for the year attributable to the